Results 181 to 190 of about 26,152,368 (390)

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

open access: yesMolecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen   +12 more
wiley   +1 more source

From inflammation to sickness and depression: when the immune system subjugates the brain

open access: yesNature Reviews Neuroscience, 2008
R. Dantzer   +4 more
semanticscholar   +1 more source

How the immune system shapes atherosclerosis: roles of innate and adaptive immunity

open access: yesNature reviews. Immunology, 2021
P. Roy, Marco Orecchioni, K. Ley
semanticscholar   +1 more source

Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?

open access: yesMolecular Oncology, EarlyView.
 
Chen‐xi Li, Zhong‐cheng Gong
wiley   +1 more source

Immune surveillance and tumors of the nervous system [PDF]

open access: bronze, 1978
Robert A. Morantz   +2 more
openalex   +1 more source

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

open access: yesMolecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma   +9 more
wiley   +1 more source

Unmutated RRAS2 emerges as a key oncogene in post-partum-associated triple negative breast cancer

open access: yesMolecular Cancer
Background Breast cancer (BC) is the most common cancer in women, with triple negative BC (TNBC) accounting for 20% of cases. While early detection and targeted therapies have improved overall life expectancy, TNBC remains resistant to current treatments.
Claudia Cifuentes   +10 more
doaj   +1 more source

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer

open access: yesMolecular Oncology, EarlyView.
G protein‐coupled receptor 4 (GPR4) is a pH‐sensing receptor activated by acidic pH. GPR4 expression is increased in patients with inflammatory bowel disease who are at high risk of developing colorectal cancer. In mouse models, loss of GPR4 attenuated tumor progression. This correlated with increased IL2 and natural killer cell activity.
Leonie Perren   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy